You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

PATANASE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Patanase, and when can generic versions of Patanase launch?

Patanase is a drug marketed by Novartis and is included in one NDA.

The generic ingredient in PATANASE is olopatadine hydrochloride. There are seventeen drug master file entries for this compound. Forty-three suppliers are listed for this compound. Additional details are available on the olopatadine hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Patanase

A generic version of PATANASE was approved as olopatadine hydrochloride by APOTEX INC on October 8th, 2014.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for PATANASE?
  • What are the global sales for PATANASE?
  • What is Average Wholesale Price for PATANASE?
Drug patent expirations by year for PATANASE
Drug Prices for PATANASE

See drug prices for PATANASE

Drug Sales Revenue Trends for PATANASE

See drug sales revenues for PATANASE

Recent Clinical Trials for PATANASE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Glenmark Pharmaceuticals Ltd. IndiaPhase 2
Alcon ResearchPhase 4
Alcon ResearchPhase 2

See all PATANASE clinical trials

Paragraph IV (Patent) Challenges for PATANASE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
PATANASE Nasal Spray olopatadine hydrochloride 0.665 mg/ Spray 021861 1 2009-06-29

US Patents and Regulatory Information for PATANASE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis PATANASE olopatadine hydrochloride SPRAY, METERED;NASAL 021861-001 Apr 15, 2008 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for PATANASE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis PATANASE olopatadine hydrochloride SPRAY, METERED;NASAL 021861-001 Apr 15, 2008 ⤷  Sign Up ⤷  Sign Up
Novartis PATANASE olopatadine hydrochloride SPRAY, METERED;NASAL 021861-001 Apr 15, 2008 ⤷  Sign Up ⤷  Sign Up
Novartis PATANASE olopatadine hydrochloride SPRAY, METERED;NASAL 021861-001 Apr 15, 2008 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for PATANASE

See the table below for patents covering PATANASE around the world.

Country Patent Number Title Estimated Expiration
Japan S6310784 DIBENZ(B,E)OXEPIN DERIVATIVE, ANTIALLERGIC AGENT AND ANTI-INFLAMMATORY AGENT ⤷  Sign Up
South Korea 20040025919 ⤷  Sign Up
Hong Kong 1059573 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for PATANASE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
3043773 21C1057 France ⤷  Sign Up PRODUCT NAME: MOMETASONE OU L'UN DE SES SELS AVEC OLOPATADINE OU L'UN DE SES SELS; NAT. REGISTRATION NO/DATE: NL52121 20211026; FIRST REGISTRATION: AT - 140638 20210426
3043773 SPC/GB21/077 United Kingdom ⤷  Sign Up PRODUCT NAME: MOMETASONE OR A SALT THEREOF AND OLOPATADINE OR A SALT THEREOF; REGISTERED: AT 140638 20210426; UK PL 25258/0331 - 0001 20210511
3043773 301154 Netherlands ⤷  Sign Up PRODUCT NAME: MOMETASON OF EEN ZOUT DAARVAN EN OLOPATADINE OF EEN ZOUT DAARVAN; NATIONAL REGISTRATION NO/DATE: RVG 126186 20211014; FIRST REGISTRATION: AT 140638 20210426
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.